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Introduction
Type 2 Diabetes Mellitus (T2DM) affects growing numbers of patients in the
United States.T2DM is characterized initially by an increase in the
production of insulin by the pancreas. Over time, as pancreatic beta cells
fail to function, levels of circulating insulin are reduced. Alterations in insulin
levels can be measured by measuring C-peptide. The purpose of this study
is to describe the effects of a class of medications known at GLP-1 analogs
on C-peptide levels in patients with T2DM.

Background/Review of Literature
Rates of T2DM in the United States are rising, with an estimated 18.8 million
diagnosed with T2DM in 2010 and 7 million undiagnosed patients. In the state of
Alabama, Diabetes Mellitus is the 6th leading cause of death. Improving methods
of assessing and treating patients with diabetes is an essential component of
reducing mortality and expense associated with the disease.
C-peptide is a 31 amino acid residue derived from proinsulin, and was first
described in 1967. As insulin is released from pancreatic beta cells, C-peptide is
cleaved from insulin; because C-peptide is not extracted from the circulation by
the liver as is insulin, it is viewed as a more direct reflection of endogenous
insulin secretion.1 Though initially considered to biologically inert, recent
research suggests that alterations in C-peptide levels may play a role in the
development of diabetic neuropathy and nephropathy in patients with Type 1
Diabetes Mellitus [T1DM].1,2 Patients with T1DM who have even minimal
sustained secretions of C-peptide have a significant reduction in risk of
microvascular complications compared to those patients in which C-peptide
secretion is absent.3,4 This may be due to the proposed anti-inflammatory effects
of C-peptide upon the vascular endothelium and vascular smooth muscle cells.5
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Methods
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The purpose of the study is to describe the effects of GLP-1 analogs upon the Cpeptide levels of patients with T2DM.

After approval by the Institutional Review Board of the University of Alabama in
Huntsville was received, a chart abstraction began. More than 5000 closed charts
from a medical practice specializing in endocrinology was conducted.
Inclusion criteria were:
•
Age of 19 years or older
•
Previous diagnosis of T2DM
•
Use of GLP-1 analog therapy (exenatide or liraglutide)
•
C-peptide measurement before initiation of GLP-1 analog therapy and minimum
of once while using the medication
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The sample is composed of 174 patients who met the criteria. The average age of the
sample population was 56.1 years. The average number of years since diagnosis of
T2DM was 13.07 years.

Table 3. Initial and follow up C-peptide levels for patients grouped by
HBA1c changes.

Elevated levels of C-peptide are an indicator of hypersecretion of insulin, caused
by the insulin resistance that is characteristic of T2DM. Patients with T2DM who
have supranormal C-peptide levels have been associated with the presence of
atherosclerotic plaques, possibly because of its role in regulating endothelial cell
function and microvascular blood flow.3,4 Elevated basal C-peptide levels in
T2DM patients have been associated with increased carotid intimal medial
thickness, and so may be viewed as a surrogate marker for the presence of
subclinical atherosclerosis in these patients.3,6

Changes in C-peptide levels after addition of GLP-1 analogs
There were no statistically significant alterations in average C-peptide levels
among patients after the addition of GLP-1 analogs, during the 12 month time
period. However, it should be noted that in the group of patients with initial Cpeptides of 0.9 – 7.1 ng/mL, the maximum initial C-peptide of 15.60 ng/mL
(dropped to 10.70 ng/mL after 12 months of therapy, with a reduction in the mean
from 3.3779 ng/mL to 2.6655 ng/mL.
Changes in HBA1c after addition of GLP-1 analogs

A recent development in the field of diabetes care has been the introduction of
GLP-1 analogs, a category of drugs that are designed to improve glycemic
control while reducing the risk of hypoglycemia in patients with T2DM. In the
authors’ clinical practice, changes in C-peptide levels have been noted after the
addition of GLP-1 analogs to the pharmacologic regimen of patients with T2DM.
Though multiple studies on the effects of GLP-1 analogs to weight, glycemic
control, and cardiovascular risk in patients with T2DM can be found in the
literature, little is known about the effects of the analogs upon discrete clinical
markers such as C-peptide and serum creatinine. There is a growing body of
evidence that underscores the importance of preserving endogenous insulin
secretion7, which is supported by clinical experiences of the authors.

There were reductions in HBA1c after the addition of GLP-1 analogs, with 62
patients displaying a >/= 3% reduction in HBA1c during the 12 month period.
Smaller decreases in HBA1c (0.1-3%) were seen in 63 patients. In the group with
initial C-peptide levels >7.1 ng/mL, 7 patients had reductions in HBA1c of 0.1>3%.
Correlation of Serum Creatinine with C-Peptide Levels
Figure 2. Number of years since diagnosis of T2DM.

Figure 3. Age of patients in the sample.

Results
Table 1.HBA1c changes derived from sample.

Table 2. Patient self-reports of hypoglycemic episodes
associated with addition of liraglutide or exenatide
to existing medication regimens.
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Figure 1. Schematic representation of human proinsulin. C-peptide is in yellow
while insullin’s A and B chains are in red.
(http://www.cebix.com/index.php/science/c-peptide biology/
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Serum creatinine and C-peptide levels prior to initiation of GLP-1 therapy were
weakly, related to one another (r = 0.215, p = 0.01). Patients who had low Cpeptide levels initially had a mean creatinine of 1.0224 mg/dL (n=67). Patients
with normal C-peptide levels initially had a mean creatinine of 1.0139 mg/dL
(n=79). After 12 months of GLP-l analog therapy in addition to the existing
treatment regimen, there was no statistically significant relationship found
between serum creatinine and C-peptide levels. The mean serum creatinine
levels in the group with low C-peptide levels after 12 months of therapy was
1.0094 mg/dL (n=53). Mean serum creatinine in the group with normal C-peptide
levels after 12 months of therapy was higher at 1.3645 mg/dL (n=31) however this
was not statistically significant.
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Though relationships between C-peptide, HBA1c, and serum creatinine overall lacked statistical
significance in this study, the results do seem to suggest that when GLP-1 analogs are added to
existing classes of antidiabetic therapy (biguanides, thiazolidinediones, insulin, and
sulfonylureas) there is the potential for reductions in both C-peptide and HBA1c levels. There
was also a lack of correlation between serum creatinine and C-peptide levels, both initially and
after 12 months of GLP-1 analog addition. However, the sample consisted of 174 patients with an
average age of 56.1 years andwho had been diagnosed with T2DM for more than 13 years. The
mean initial serum creatinine of this sample population was within normal range, regardless of Cpeptide levels, which may be atypical when considering the natural progression of T2DM. The
incidence of self-reported hypoglycemia was 20% in the sample population, which is higher than
the 11-12% reported in other studies.

Conclusions and Future Research
This study reports real-world effects of GLP-1 analog use in patients with T2DM upon clinical
markers linked to microvascular and macrovascular complications. Outcomes and effectiveness
research involving larger groups of patients for more sustained time periods would be beneficial
in determining the significance of GLP-1 analog use upon clinical markers of complications in this
patients affected by T2DM. In addition, research upon the identification and description of the the
receptor for proinsulin C-peptide, including the possible differences in receptor sites and action
for patients with both T1DM and T2DM, is also warranted.

